10 Any case of keratitis in returning travelers, especially those wearing contact lenses should be suspected to be caused by fungi. A collaborative effort should be exercised in identifying the fungus to the species level so that appropriate treatment is delivered and damage to eyesight is averted. The authors state they have no conflicts of interest to declare. “
“This Editorial refers to the articles by Ritchie et al., pp. 298–307 and Leshem et al., pp. 308–310 of this

issue. Although it is best to prevent acute mountain sickness (AMS)[1] by gradual ascent without using any drugs, this may not always be an option in many settings. Rescuers may need to go up rapidly to high altitudes; or logistically, owing to a lack of camp site, it may not be possible for trekkers and climbers to spend the night at an Dabrafenib supplier optimal altitude. Furthermore, airports in places like Lhasa, Tibet (3,490 m) and La Paz, Bolivia (4,058 m) may cause travelers to arrive at high altitude without the ability to acclimatize

en route. Some people who are predisposed to AMS may be protected by taking a prophylactic drug while ascending high altitudes. Many, such as pilgrims, often disregard strongly delivered advice about gradual ascent in their single-minded determination BMS354825 to ascend the sacred site.[2] In addition, there is a fast-growing population of climbers in pursuit of a summit who are being advised by physicians to use prophylactic medicine to both improve performance 3-oxoacyl-(acyl-carrier-protein) reductase and achieve summit success. Poor knowledge and lack of awareness of side effects may lead to widespread misuse of drugs. Finally, sudden military deployment to high altitude regions of the world, such as the Hindu Kush mountains in Afghanistan, may necessitate drug prophylaxis for the prevention of AMS. Two articles[3, 4] in the present issue deal with the use of acetazolamide at high altitude in the prevention of altitude illness. In 1965, Cain and Dunn[5] were the first to

show that acetazolamide increased ventilation resulting in increased partial pressure of oxygen and decreased partial pressure of carbon dioxide. The findings of hyperventilation and increase in oxygen levels in the blood brought on by the drug were exploited in subsequent years in dealing with the effects of hypoxia of high altitude.[1, 6] In this issue, the meta-analysis[3] studying the prevention of AMS using acetazolamide covers 16 studies. No study protocols were available for the authors to independently review these. However, the meta-analysis was strengthened because only randomized, placebo-controlled trials were included in the study. Importantly, this meta-analysis included studies done after 2000. In a publication in 2000, Dumont and colleagues[7] had arbitrarily shown that only 750 mg/day of acetazolamide would prevent AMS. By including many more studies [eg, see Refs [8-10]] since 2000, it was reassuring to note that a much lower dose (250 mg/day) was adequate for prevention.